The Q4 2026 clinical data update for APR-1051 is the key catalyst; the $41.2M cash runway into Q1 2028 reduces near-term dilution risk. Monitor enrollment pace and any early efficacy signals from the ACESOT-1051 trial.
Price Chart
Executive Summary
Aprea Therapeutics reported Q2 2026 results with a net loss of $3.6M ($-0.07/share), widening from a $3.2M loss in Q2 2025, driven by increased R&D spending on the lead WEE1 inhibitor APR-1051. The company highlighted accelerating enrollment in the Phase 1 ACESOT-1051 trial, with a next clinical data update expected in Q4 2026, and maintained a cash runway into Q1 2028. The $8M market cap stock is a pre-revenue clinical-stage biotech, making the EPS miss a mechanical artifact of share count changes rather than a fundamental deterioration, while the pipeline progress provides a modest positive catalyst.
Key Financial Metrics
Key Facts
- Net loss of $3.6M ($-0.07/share) for Q2 2026 vs $3.2M ($-0.53/share) in Q2 2025
- Cash and cash equivalents of $41.2M as of June 30, 2026, up from $14.6M at Dec 31, 2025
- R&D expenses increased to $2.5M from $1.9M, driven by APR-1051 trial costs
- Enrollment accelerating in Phase 1 ACESOT-1051 trial of APR-1051; next data update expected Q4 2026
- Cash runway into Q1 2028
- Weighted-average shares outstanding increased to 53.5M from 6.1M due to $30M private placement
Financial Impact
Net loss widened by $0.4M YoY; cash position strengthened by $26.6M from year-end 2025
Risk Factors
- Pre-revenue clinical-stage company with no approved products
- Dependence on single lead candidate APR-1051
- Significant share dilution from $30M private placement
- Clinical trial failure risk for APR-1051
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343645 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 28, 2026 8w ago | 8-K | $0.8386 | awaiting T+60 | — | $0.5180 (−38.23%) |
Aug 12, 2026 10w ago | 8-K | $0.6830 | awaiting T+60 | — | $0.5180 (−24.16%) |
Aug 12, 2026 10w ago | Press Release | $0.6830 | awaiting T+60 | — | $0.5180 (−24.16%) |
May 13, 2026 23w ago | 8-K | $0.8800 $0.6503 | ▼ −26.10% | ▼ −30.54% | $0.5180 (−41.14%) |
May 13, 2026 23w ago | Press Release | $0.8800 $0.6503 | ▼ −26.10% | ▼ −30.54% | $0.5180 (−41.14%) |
Apr 30, 2026 25w ago | DEFA14A | $0.8000 $0.6247 | ▲ +21.91% | ▲ +25.02% | $0.5180 (+35.25%) |
Apr 22, 2026 26w ago | S-3 | $0.8840 $0.6690 | ▲ +24.32% | ▲ +29.34% | $0.5180 (+41.40%) |
Apr 21, 2026 26w ago | Press Release | $0.9070 $0.6900 | ▼ −23.93% | ▼ −30.82% | $0.5180 (−42.89%) |
Mar 31, 2026 29w ago | Insider Cluster | $0.7630 $0.7900 | ▲ +3.54% | ▼ −8.84% | $0.5180 (−32.11%) |
Mar 20, 2026 31w ago | EFFECT | $0.7620 $0.6990 | ▼ −8.27% | ▼ −22.69% | $0.5180 (−32.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers